J. Goldman & CO LP Fulcrum Therapeutics, Inc. Transaction History
J. Goldman & CO LP
- $3.35 Billion
- Q3 2025
A detailed history of J. Goldman & CO LP transactions in Fulcrum Therapeutics, Inc. stock. As of the latest transaction made, J. Goldman & CO LP holds 135,000 shares of FULC stock, worth $1.17 Million. This represents 0.04% of its overall portfolio holdings.
Number of Shares
135,000
Previous 67,500
100.0%
Holding current value
$1.17 Million
Previous $464,000
153.66%
% of portfolio
0.04%
Previous 0.01%
Shares
5 transactions
Others Institutions Holding FULC
# of Institutions
133Shares Held
55.4MCall Options Held
176KPut Options Held
13.5K-
Ra Capital Management, L.P. Boston, MA10.2MShares$88.7 Million1.53% of portfolio
-
Suvretta Capital Management, LLC New York, NY5.38MShares$46.7 Million1.41% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA5.25MShares$45.5 Million5.13% of portfolio
-
Black Rock Inc. New York, NY4.8MShares$41.6 Million0.0% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT4.67MShares$40.5 Million1.65% of portfolio
About Fulcrum Therapeutics, Inc.
- Ticker FULC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,038,900
- Market Cap $451M
- Description
- Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...